Related Experiment Video
Updated: Mar 12, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
627
Targeting the Endocannabinoid System in Psychiatric Illness
Martin A Katzman1, Melissa Furtado, Leena Anand
1From the *START Clinic for Mood and Anxiety Disorders; †The Northern Ontario School of Medicine, Thunder Bay; ‡Department of Psychology, Lakehead University, Thunder Bay; and §Adler School of Professional Studies, Toronto, Ontario, Canada.
Journal of Clinical Psychopharmacology
|November 5, 2016
Summary
The endocannabinoid system shows promise for treating psychiatric disorders like depression and anxiety. Further research is needed to understand cannabinoid treatments and their safety for mental health conditions.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Global rise in psychiatric disorders necessitates novel treatments.
- The endocannabinoid system's role in medical illnesses suggests potential in psychiatry.
- Current psychiatric treatments have limitations in remission rates and patient outcomes.
Purpose of the Study:
- To review the endocannabinoid system's involvement in psychiatric disorders.
- To explore the potential of cannabinoid treatments for conditions including schizophrenia, depression, anxiety, PTSD, and ADHD.
- To address controversies and limitations surrounding cannabinoid-based therapies.
Main Methods:
- Literature review of studies on the endocannabinoid system and psychiatric disorders.
- Analysis of research on cannabinoid efficacy and safety in psychiatric populations.
- Examination of factors influencing cannabinoid treatment outcomes, such as cannabinoid content (THC vs. CBD) and study design.
Main Results:
- The endocannabinoid system is implicated in the pathophysiology of several psychiatric disorders.
- Evidence suggests potential therapeutic benefits of cannabinoids for conditions like anxiety and PTSD.
- Concerns exist regarding adverse effects and the need for rigorous study designs.
Conclusions:
- The endocannabinoid system represents a promising target for novel psychiatric treatments.
- Careful consideration of cannabinoid content and study methodology is crucial for evaluating treatment safety and efficacy.
- Further research is warranted to establish the therapeutic value of cannabinoid treatments in psychiatry.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
648
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
648
01:15G Protein-coupled Receptors
18.8K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.8K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.1K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.1K
01:28Drug Therapy
364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
364
01:28Psychosis and Antipsychotic Drugs: Overview
1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
889
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
889